2 patients now with a complete response who had advanced AML.
the first patient from Phase 1A is cancer free after 4 years now. Let’s hope the second patient is also
remember, these are patients who relapsed or were not eligible for other earlier lines of AML treatments.
this augurs really well for CHMs Advent AML trial with MD Anderson which is targeting patients with AML who are not eligible for standard of care first line therapy (chemo + stem cell transplants). As Doctor Maiti said the science for the CORE NK combo therapy he proposed was compelling. And because we are treatin So g patients in a first line setting, we can expect even better results because the patient is not as immunocompromised and the cancer in the bone marrow not as pronounced.
CHM Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)